KYTXKyverna Therapeutics Inc. Common Stock

8.420USD-5.07%Mkt Cap: 520.72M $P/E:

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product…